|Day Low/High||2.75 / 2.81|
|52 Wk Low/High||1.41 / 8.61|
Results Show Statistically Significant Improvement in Sweat Chloride, Body Mass Index, Weight and Blood Glucose
BOSTON, June 1, 2018 /PRNewswire/ -- Proteostasis Therapeutics, Inc. (NASDAQ:PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic fibrosis (CF) and other diseases caused by...
Investors in Proteostasis Therapeutics Inc saw new options begin trading this week, for the May 18th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the PTI options chain for the new May 18th contracts and identified the following put contract of particular interest.
Program to Pursue Broad Label for PTI-428 as an Add-On Therapy to CFTR Modulator Based Treatment
Glancy Prongay & Murray LLP ("GPM") announces an investigation on behalf of Proteostasis Therapeutics, Inc.
Designation granted for PTI-428 for the treatment of CF patients based on the results from a recent Phase 2, randomized, placebo controlled study
Triple Combination of PTI-428, PTI-801 and PTI-808 Study to Initiate Dosing in CF Patients in 1H'18
Company to Host Conference Call and Webcast Today at 5:00 p.m. ET
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.